Company / Free Cash Flow
GYRE THERAPEUTICS, INC. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$180.0K
FY2025
5-year range
-$84.6M / $5.7M
FY2021-FY2025
Trend
+97.0%
vs FY2024
Sector context
#66 of 194
Health Care
What the data says
At -$180,000, GYRE THERAPEUTICS, INC.'s free cash flow ranks #66 of 194 in the Health Care sector. Declined from $6M to -$180,000 over the past 2 years.
Based on SEC 10-K filings.
-$180,000 in FY2025.
Declined from $6M to -$180,000 over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#66 of 194 in Health CareTop 34% of 194This company -$180.0K Sector average $470.8M
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 97.0% year-over-year.
- Ranks #66 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2023.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$180.0K | +97.0% |
| FY2024 | -$6.0M | -204.6% |
| FY2023 | $5.7M | +0.0% |
| FY2022 | $5.7M | +106.7% |
| FY2021 | -$84.6M | - |
| FY2020 | - | - |
| FY2019 | -$43.7M | -118.8% |
| FY2018 | -$20.0M | +0.0% |
| FY2017 | -$20.0M | -5.4% |
| FY2016 | -$18.9M | +2.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026